

Lung Cancer: Small Cell Lung Cancer Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ Pathology: _____

Stage: IA IB IIA IIB IIIA IIIB IV Recurrent

Line of Treatment: Neoadjuvant/Pre-Op Adjuvant/Post-Op First Line Second Line Third Line Third Line+ Maintenance

ECOG Performance Status: 0 1 2 3 4

Biomarker:

ALK status: Positive Negative Not reported

EGFR: Mutation Wild type Not reported

BRAF: V600E Mutation V600K Mutation Wild type Not reported

MET amplification: Positive Negative Not reported

RET gene rearrangement: Absent Present Not reported

ROS1 rearrangement: Positive Negative Not reported

Limited Stage | Primary, Adjuvant, or First Line Therapy (1st line)

Carboplatin (Paraplatin) and etoposide (Toposar) ± XRT

Cisplatin (Platinol) and etoposide (Toposar) ± XRT

Extensive Stage | First line of therapy (1st line)

Carboplatin (Paraplatin) and etoposide (Toposar)

Second and subsequent lines of therapy (2nd line +) | Relapse greater than 6 months

Carboplatin (Paraplatin) and etoposide (Toposar)

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

